pharmaphorum

FEBRUARY 23, 2022

In this context, the 2 nd Annual Gene Therapy Patient Engagement Summit will unite patient advocacy and engagement leaders from gene therapy and gene editing drug developers, patient groups and patients themselves to address the specific challenges of genetic therapy patient engagement, generating actionable insights through detailed case studies (..)

FDA 52

FDA 52

Pharmaceutical Technology

APRIL 5, 2023

This includes the first potential approval of a CRISPR-based gene therapy called exa-cel , which is developed by CRISPR Therapeutics and Vertex Pharmaceuticals. But I think we’ve never had more tools than we have now in synthetic biology, genetic engineering, enhanced potency design switches and CRISPR.

FDA 59

FDA Immunization 59

ISPE

OCTOBER 27, 2022

What did companies learn during the early development stages for CRISPR/CAS therapies? The conference speakers come from around the world and provide unique, multi-faceted perspectives on the topics. Setting up a fill-finish process for a high-potent, oncology product in a prefilled syringe: what were the unique challenges?

Dosage 98

Dosage Vaccines FDA Documentation 98

pharmaphorum

MARCH 19, 2021

Protein misfolding has become a hot topic in the biopharma industry, with a clutch of emerging companies targeting the broad range of diseases that feature aberrant proteins.

103

103

Pharmaceutical Technology

OCTOBER 5, 2022

In September this year, the company and Scribe Therapeutics entered a strategic partnership to expedite the development of CRISPR-based cell therapies for cancer. Topic sponsors are not involved in the creation of editorial content. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

52

52

pharmaphorum

NOVEMBER 1, 2022

Further topics to be examined comprise of novel RNA modalities encompassing self-amplifying RNA, saRNA, circular RNA, lnc RNA and many more. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%.

52

52

ISPE

JUNE 8, 2023

The introduction of groundbreaking technologies such as CRISPR gene editing has already produced significant improvements in the treatment of patients, and as this technology continues to evolve, gene therapies hold the potential to provide even more miraculous results.

98

98

Pharma Marketing Network

DECEMBER 21, 2020

conflation of traditional gene therapy and gene editing; the use of “CRISPR” as a synonym, rather than a synecdoche, for gene editing; and confusion between in vivo and ex vivo applications of these technologies). This makes it challenging for them to reconstruct their prior state of mind in which they did not understand the topic. #5.

Communication 52

Communication Immunization 52

The Checkup by Singlecare

AUGUST 5, 2023

You have every right to be interested in this topic, and as with any polarizing issue, it is best to be well-informed. CRISPR is a well-known example of a gene editing technique. Gene therapy techniques Using technology such as CRISPR, a faulty gene in a cell can be cut out, and a new sequence of code can be inserted.

Immunization 52

Immunization FDA 52

pharmaphorum

APRIL 20, 2022

The potential of CRISPR technology has been a hot topic in the industry ever since it was first developed, but as trials progress further into the clinic, what therapeutic areas could be set to benefit? Ben Hargreaves takes a look at why oncology could be one of the major beneficiaries of a growing pipeline of CRISPR therapeutics.

Chemotherapy 52

Chemotherapy Immunization 52

Pharmaceutical Technology

MAY 17, 2023

Scribe Therapeutics has entered a strategic collaboration with Eli Lilly and Company subsidiary Prevail Therapeutics for accelerating in vivo CRISPR-based therapies to target the causes of serious neurological and neuromuscular diseases. Topic sponsors are not involved in the creation of editorial content.

Immunization 52

Immunization 52

Pharmaceutical Technology

APRIL 4, 2023

Vertex Pharmaceuticals and CRISPR Therapeutics have completed the rolling submission of biologics licence applications (BLAs) to the US Food and Drug Administration (FDA) for exagamglogene autotemcel (exa-cel) to treat sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

FDA 98

FDA 98

Pharmaceutical Technology

JANUARY 10, 2023

AskBio CEO Sheila Mikhail said: “The collaboration pairs AskBio’s expertise in synthetic DNA and CRISPR applications with ReCode’s novel SORT LNP delivery technology to potentially discover new genetic medicines. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper.

Communication 52

Communication 52

Pharma Marketing Network

JANUARY 20, 2021

Here, we provide some insights on 3 key topics based on panel discussions with industry leaders at this year’s event. #1. In other areas of the industry (such as cell and genetic medicine development) progress continued at an impressively brisk pace despite the pandemic.

Vaccines 52

Vaccines Immunization Communication 52